We are live on ! Find out more
DFTX

Definium Therapeutics

135 hedge funds and large institutions have $327M invested in Definium Therapeutics in 2024 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 31 increasing their positions, 17 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,724% more capital invested

Capital invested by funds: $18M → $327M (+$310M)

364% more call options, than puts

Call options by funds: $28.4M | Put options by funds: $6.11M

300% more funds holding in top 10

Funds holding in top 10: 14 (+3)

254% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 13

82% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 17

72.01% more ownership

Funds ownership: 12.24%84.24% (+72%)

30% more funds holding

Funds holding: 104135 (+31)

Holders
135
Holders Change
+31
Holders Change %
+29.81%
% of All Funds
1.94%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.06%
New
46
Increased
31
Reduced
17
Closed
13
Calls
$28.4M
Puts
$6.11M
Net Calls
+$22.3M
Net Calls Change
+$16.9M
Name Holding Trade Value Shares
Change
Change in
Stake
CSS
51
Cubist Systematic Strategies
Connecticut
$269K +$163K +28,618 New
Bank of America
52
Bank of America
North Carolina
$246K -$33.4K -5,860 -18%
VF
53
Virtu Financial
New York
$239K +$145K +25,440 New
SAG
54
SageView Advisory Group
California
$238K +$15.1K +2,648 New
GS
55
GTS Securities
New York
$234K +$142K +24,921 New
Commonwealth Equity Services
56
Commonwealth Equity Services
Massachusetts
$234K +$47.5K +8,322 +50%
Fidelity Investments
57
Fidelity Investments
Massachusetts
$231K +$4.39K +770 +3%
UBS Group
58
UBS Group
Switzerland
$229K +$137K +23,981 +5,951%
RG
59
Rathbones Group
United Kingdom
$227K -$4.56K -800 -3%
B
60
Bailard
California
$227K +$38.8K +6,800 +39%
YIH
61
Y-Intercept (HK)
Hong Kong
$219K +$36.9K +6,463 +38%
Two Sigma Advisers
62
Two Sigma Advisers
New York
$206K +$125K +21,917 New
MMPW
63
Mitchell McLeod Pugh & Williams
Alabama
$188K
SFA
64
Sequoia Financial Advisors
Ohio
$168K +$102K +17,912 New
LP
65
LMR Partners
United Kingdom
$154K +$93.4K +16,374 New
CIM
66
Chiron Investment Management
New York
$150K +$90.8K +15,932 New
FDCDDQ
67
Federation des caisses Desjardins du Quebec
Quebec, Canada
$149K -$376 -66 -0.5%
PI
68
PEAK6 Investments
Illinois
$145K +$88.1K +15,454 New
Mercer Global Advisors
69
Mercer Global Advisors
Colorado
$140K +$85.1K +14,928 New
RJFSA
70
Raymond James Financial Services Advisors
Florida
$129K +$78.5K +13,762 New
PCMH
71
Polymer Capital Management (HK)
Hong Kong
$112K +$68K +11,926 New
William Blair & Company
72
William Blair & Company
Illinois
$107K +$64.7K +11,341 New
BHCM
73
Brevan Howard Capital Management
Jersey
$100K +$60.7K +10,649 New
Thrivent Financial for Lutherans
74
Thrivent Financial for Lutherans
Minnesota
$94K +$57.2K +10,027 New
Barclays
75
Barclays
United Kingdom
$86K

DFTX Hedge Fund Activity: Q1 2024 in Review

135 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q1 2024, worth a combined $327M — up 1,724% from $18M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new DFTX positions and 13 closed out — a net gain of 33 holders — while 31 added to existing stakes and 17 trimmed.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $38M. The largest seller was Ikarian Capital, cutting an estimated $1.72M.

  • 135 institutional investors held Definium Therapeutics (DFTX) as of Q1 2024, up from 104 in Q4 2023.
  • Funds reported $327M of Definium Therapeutics stock for Q1 2024, up 1,724% quarter-over-quarter.
  • 46 funds opened new Definium Therapeutics positions in Q1 2024 and 13 closed out, a net change of +33 holders.
  • The largest Definium Therapeutics buyer in Q1 2024 was Deep Track Capital, an estimated $38M added.
  • The largest Definium Therapeutics seller in Q1 2024 was Ikarian Capital, an estimated $1.72M sold.

Based on aggregated 13F filings for Q1 2024.